<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html
  SYSTEM "about:legacy-compat">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><script type="text/javascript" src="../js/jr.boots.js"></script><title>
         NOLVADEX (tamoxifen citrate) TABLETS Medical Information
      </title>
      <meta charset="utf-8" />
      <meta name="apple-mobile-web-app-capable" content="no" />
      <meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no" />
      <link href="http://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&amp;subset=latin" rel="stylesheet" type="text/css" />
      <link rel="stylesheet" href="../lib/css/normalize.css" />
      <link rel="stylesheet" href="../lib/css/figpopup.css" />
      <link rel="stylesheet" href="../css/jr.ui.css" />
      <link rel="stylesheet" href="../css/jr.pagemanager.css" />
      <link rel="stylesheet" href="../css/jr.pageturnsensor.css" />
      <link rel="stylesheet" href="../css/jr.pageprogressbar.css" />
      <link rel="stylesheet" href="../css/jr.objectbox.css" />
      <link rel="stylesheet" href="../css/jr.panel.css" />
      <link rel="stylesheet" href="../css/jr.panel.typo.css" />
      <link rel="stylesheet" href="../css/jr.panel.cmap.css" />
      <link rel="stylesheet" href="../css/jr.panel.istrip.css" />
      <link rel="stylesheet" href="../css/jr.fip.css" />
      <link rel="stylesheet" href="../css/jr.small.screen.css" />
      <link rel="stylesheet" href="../css/jr.content.css" />
      <link rel="stylesheet" href="../lib/css/citationexporter.css" />
   </head>
   <body>
      <div id="jr" data-jr-path="../">
         <div class="jr-unsupported">
            <table class="modal">
               <tr>
                  <td><span class="attn inline-block"></span><br />Your browser does not support the NLM
                     PubReader view.<br />Go to <a href="https://www.ncbi.nlm.nih.gov/pmc/about/pr-browsers/">this page</a> to see a
                     list of supporting browsers.
                  </td>
               </tr>
            </table>
         </div>
         <div id="jr-ui" class="hidden">
            <nav id="jr-head">
               <div class="flexh tb">
                  <div id="jr-tb1"><a id="jr-pdf-sw" href="https://s3.amazonaws.com/interactive-std-response-letter/tamoxifen-medical-information-letter.pdf" class="btn wsprkl">PDF</a></div>
                  <div class="jr-rhead f1">
                     <div class="t">NOLVADEX (tamoxifen citrate) TABLETS</div>
                     <div class="j">MEDICAL INFORMATION
                     </div>
                  </div>
                  <div id="jr-tb2"><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings, typography and Help with NLM PubReader"><img src="../img/pmc.gear.svg" alt="settings &amp; help" class="svg" /></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><img src="../img/pmc.mg.svg" alt="Search on this page" class="svg" /></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Article Navigation"><img src="../img/pmc.cmap.svg" alt="Table of Content" class="svg" /></a></div>
               </div>
            </nav>
            <nav id="jr-dash" class="noselect">
               <div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page">
                     <svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 100 100" preserveaspectratio="none">
                        <path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path>
                        <text x="20" y="28" textlength="60" style="font-size:25px">Prev</text>
                     </svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page">
                     <svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 100 100" preserveaspectratio="none">
                        <path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path>
                        <text x="20" y="28" textlength="60" style="font-size:25px">Next</text>
                     </svg></a></div>
               <div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar">
                     <svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 100 100" preserveaspectratio="none">
                        <rect x="10" y="40" width="20" height="20"></rect>
                        <rect x="40" y="40" width="20" height="20"></rect>
                        <rect x="70" y="40" width="20" height="20"></rect>
                     </svg></a></div>
               <nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous">
                     <svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 100 100" preserveaspectratio="none">
                        <path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path>
                        <text x="35" y="25" textlength="60" style="font-size:25px">Prev</text>
                     </svg></a><a id="jr-is-next" href="#" class="hidden" title="Next">
                     <svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 100 100" preserveaspectratio="none">
                        <path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path>
                        <text x="15" y="25" textlength="60" style="font-size:25px">Next</text>
                     </svg></a></nav>
               <nav id="jr-progress"></nav>
            </nav>
            <aside id="jr-cmap-p" class="hidden flexv">
               <div class="tb sk-htbar flexh">
                  <div><a class="jr-p-close btn wsprkl">Done</a></div>
                  <div class="title-text f1">Letter navigation</div>
               </div>
               <div class="cnt lol f1"></div>
            </aside>
            <aside id="jr-help-p" class="hidden flexv">
               <div class="tb sk-htbar flexh">
                  <div><a class="jr-p-close btn wsprkl">Done</a></div>
                  <div class="title-text f1">Settings &amp; Help</div>
               </div>
               <div class="cnt f1">
                  <div id="jr-typo-p" class="typo">
                     <div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div>
                     <div><a class="bcol-auto btn wsprkl">
                           <svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 200 100" preserveaspectratio="none">
                              <text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textlength="180">AUTO</text>
                           </svg></a><a class="bcol-1 btn wsprkl">
                           <svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 100 100" preserveaspectratio="none">
                              <path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path>
                           </svg></a><a class="bcol-2 btn wsprkl">
                           <svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 100 100" preserveaspectratio="none">
                              <path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path>
                           </svg></a></div>
                  </div>
                  <div class="lol"><a id="jr-helpobj-sw" data-path="../" data-href="../img/help.xml" href="">Help with PubReader</a><a href="mailto:your_name@your_domain?subject=PubReader%20feedback%20/%20PMC13901%20/%20sid:5D1947B4B2C0C061_0014SID%20/%20phid:5D1947B4B2B2250100000000000E000C.2">Feedback / suggestions</a><a id="jr-about-sw" data-path="../" data-href="../img/about.xml" href="">About PubReader</a></div>
               </div>
            </aside>
            <aside id="jr-objectbox" class="thidden hidden">
               <div class="jr-objectbox-close wsprkl">✘</div>
               <div class="jr-objectbox-inner cnt">
                  <div class="jr-objectbox-drawer"></div>
               </div>
            </aside>
            <nav id="jr-pm-left" class="hidden">
               <svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 100 1000" preserveaspectratio="none">
                  <text x="850" y="-20" transform="rotate(90)" textlength="150" font-size="23">Previous Page</text>
               </svg>
            </nav>
            <nav id="jr-pm-right" class="hidden">
               <svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 100 1000" preserveaspectratio="none">
                  <text x="850" y="-70" transform="rotate(90)" textlength="150" font-size="23">Next Page</text>
               </svg>
            </nav>
            <nav id="jr-fip" class="hidden">
               <nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><img src="../img/pmc.mg.svg" alt="Find" class="svg" /></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav>
               <nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav>
            </nav>
         </div>
         <div id="jr-epub-interstitial" class="hidden">
            <h2 role="dialog">Making articles easier to read in PMC</h2>
            <div class="contentpane">
               <p> We are experimenting with display styles that make it easier to read articles in
                  PMC. The ePub format uses eBook readers, which have several "ease of reading" features
                  already built in.
               </p>
               <p> The ePub format is best viewed in the iBooks reader. You may notice problems with
                  the display of certain parts of an article in other eReaders.
               </p>
               <p> Generating an ePub file may take a long time, please be patient. </p>
            </div>
            <div class="buttonpane lol"><a id="cancelEpub" style="float: right">Cancel</a><a id="downloadEpub" style="float: left">Download article</a></div>
         </div><a id="jr-welcome-trigger" class="hidden">t</a><div id="jr-welcome" class="hidden">
            <h2 role="dialog">Welcome to PubReader!</h2>
            <div class="contentpane">
               <p> Click on <a class="btn"><img src="../img/pmc.gear.svg" alt="settings &amp; help" class="svg" /></a> above to:

               </p>
               <ul>
                  <li>Get help with PubReader, or </li>
                  <li>Switch to the classic article view.</li>
               </ul>
            </div>
            <div class="buttonpane lol"><a id="okayWelcome" class="btn centerbutton">Okay</a></div>
         </div>
         <div id="jr-content">


            <article xmlns:t="http://www.ncbi.nlm.nih.gov/ns/test" data-type="main">

               <div class="bpd">

                  <div class="t"> <b>NOLVADEX</b> (tamoxifen citrate) TABLETS</div>

                  <div class="p"> MEDICAL INFORMATION</div>

               </div>

               <header class="fm-sec">

                 <h2 class="content-title" id="__title">DOSAGE OF NOLVADEX (TAMOXIFEN CITRATE) TABLETS FOR ADJUVANT TREATMENT OF BREAST CANCER</h2>
                  <h1 class="content-title">
                  </h1>

                  <!-- <p class="contribs"> Medical Information </p> -->

               </header>

               <div id="__abstractid" class="sec">

                  <h3 class="head no_bottom_margin" id="__abstractidtitle">Response to Unsolicited Request</h3>
                  <!--article-meta-->

                  <div>

                     <div id="__sec1" class="sec sec-first">

                        <p id="__p1">Thank you for requesting additional information regarding the dosage of NOLVADEX (tamoxifen citrate) tablets for the adjuvant treatment of breast cancer.
                        </p>

                        <p id="__p1">The contained information is being provided in response to an unsolicited request for medical information. This letter does not recommend unapproved use of tamoxifen or any other available agents and does not intent to replace medical advice offered by physicians or healthcare professionals. This letter provides a summary of relevant medical information available at the time of writing. The included summary may not represent all information on this topic. This document is approved for use in the United States only.
                        </p>

                     </div>

                     <div id="__sec2" class="sec">

                        <h3>RESPONSE IN BRIEF<sup>1</sup></h3>

                        <p id="__p2">For women with breast cancer, the recommended dosage of NOLVADEX (tamoxifen citrate) tablets is 20–40 mg daily. In clinical trials of NOLVADEX, there was no indication that doses greater than 20 mg per day were more effective. Current data from clinical trials support 5 years of adjuvant NOLVADEX therapy for patients with breast cancer.
                        </p>

                     </div>

                     <h2>INDICATIONS AND USAGE<sup>1</sup></h2>

                     <div id="__sec3" class="sec">

                        <h4><i>Metastatic Breast Cancer</i></h4>

                        <p id="__p3">NOLVADEX is effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, NOLVADEX is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from NOLVADEX therapy.
                        </p>

                     </div>

                     <div id="__sec4" class="sec">

                        <h4><i>Adjuvant treatment of breast cancer</h4></i>

                        <p id="__p4"> NOLVADEX is indicated for the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some NOLVADEX adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes.
                        </p>

                        <p id="__p5"> NOLVADEX is indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant NOLVADEX therapy is likely to be beneficial.
                        </p>

                        <p id="__p6"> NOLVADEX reduces the occurrence of contralateral breast cancer in patients receiving adjuvant NOLVADEX therapy for breast cancer.
                        </p>

                     </div>

                     <div id="__sec5" class="sec">

                        <h4><i>Ductal carcinoma in situ (DCIS)</h4></i>

                        <p id="__p7"> In women with DCIS, following breast surgery and radiation, NOLVADEX is indicated to reduce the risk of invasive breast cancer. The decision regarding therapy with NOLVADEX for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of NOLVADEX therapy. Current data from clinical trials support five years of adjuvant NOLVADEX therapy for patients with breast cancer.
                        </p>

                     </div>

                     <div id="__sec6" class="sec">

                        <h4><i>Reduction in breast cancer incidence in high risk women</h4></i>

                        <p id="__p8"> NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality. NOLVADEX is indicated only for high-risk women. “High risk” is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer 1.67%, as calculated by the Gail Model.
                        </p>

                     </div>

                  </div>

               </div>

               <div id="__sec4" class="sec">

                  <h2 class="head no_bottom_margin" id="__sec4title">CONTRAINDICATIONS<sup>1</sup></h2>

                  <p id="__p9">NOLVADEX is contraindicated in patients with known hypersensitivity to the drug or any of its ingredients.
                  </p>

                  <p id="__p10">Reduction in breast cancer incidence in high risk women and women with DCIS.
                  </p>

                  <p id="__p11">NOLVADEX is contraindicated in women who require concomitant coumarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus.
                  </p>

               </div>

               <div id="__sec5" class="sec">

                  <h2 class="head no_bottom_margin h-blackbox" id="__sec5title">BLACK BOX WARNING<sup>1</sup></h2>

                  <div class="sec-blackbox">

                    <p id="__p12"><b>WARNING:</b> For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer: Serious and life-threatening events associated with NOLVADEX in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence rates for these events were estimated from the NSABP P-1 trial. Uterine malignancies consist of both endometrial adenocarcinoma (incidence rate per 1,000 women-years of 2.20 for NOLVADEX vs 0.71 for placebo) and uterine sarcoma (incidence rate per 1,000 women-years of 0.17 for NOLVADEX vs 0.0 for placebo)*. For stroke, the incidence rate per 1,000 women years was 1.43 for NOLVADEX vs 1.00 for placebo**. For pulmonary embolism, the incidence rate per 1,000 women-years was 0.75 for NOLVADEX versus 0.25 for placebo**. Some of the strokes, pulmonary emboli, and uterine malignancies were fatal. Health care providers should discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and women with DCIS considering NOLVADEX to reduce their risk of developing breast cancer. The benefits of NOLVADEX outweigh its risks in women already diagnosed with breast cancer.
                    </p>

                  </div>

                  <div class="tblwrap-foot">

                    <p>*Updated long-term follow-up data (median length of follow-up is 6.9 years) from NSABP P-1 study
                    <br>
                    **See Table 3 under CLINICAL PHARMACOLOGY-Clinical Studies
                    </p>

                  </div>

               </div>

               <div id="__sec6" class="sec">

                  <h2 class="head no_bottom_margin" id="__sec6title">WARNINGS AND PRECAUTIONS</h2>
                  <p id="__p13"><b>Uterine malignancies:</b> Promptly evaluate abnormal vaginal bleeding in a woman with current or past tamoxifen use
                  </p>

                  <p id="__p14"><b>Thromboembolic events:</b> Risk increases with coadministered chemotherapy. For treatment of breast cancer, consider risks and
benefits in patients with a history of thromboembolic events
                  </p>

                  <p id="__p15"><b>Embryo-fetal toxicity:</b> Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception
                  </p>

                  <p id="__p16"><b>Effects on the liver:</b> Liver cancer and liver abnormalities, some fatal, have occurred. Perform periodic liver function testing
                  </p>

               </div>

               <div id="__sec7" class="sec">

                  <h2 class="head no_bottom_margin" id="__sec7title">BACKGROUND</h2>

                  <h4><i>Pharmacology<sup>1,2</sup></h4></i>
                  <p id="__p17">The in vitro IC50 of tamoxifen for MCF7 breast cancer cells has been reported as 0.2–2 ng/mL.<sup>2</sup>
                  </p>

                  <p id="__p18">Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing. The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days. The average peak plasma concentration of N-desmethyl tamoxifen, the major active metabolite of tamoxifen, is 15 ng/mL (range 10 to 20 ng/mL). Chronic administration of 10 mg tamoxifen given twice daily for 3 months to patients results in average steady-state plasma concentrations of 120 ng/mL (range 67-183 ng/mL) for tamoxifen and 336 ng/mL (range 148-654 ng/mL) for N-desmethyl tamoxifen. The average steady-state plasma concentrations of tamoxifen and N-desmethyl tamoxifen after administration of 20 mg tamoxifen once daily for 3 months are 122 ng/mL (range 71-183 ng/mL) and 353 ng/mL (range 152-706 ng/mL), respectively. After initiation of therapy, steady state concentrations for tamoxifen are achieved in about 4 weeks and steady-state concentrations for N-desmethyl tamoxifen are achieved in about 8 weeks, suggesting a half-life of approximately 14 days for this metabolite. In a steady-state, crossover study of 10 mg NOLVADEX tablets given twice a day vs. a 20 mg NOLVADEX tablet given once daily, the 20 mg NOLVADEX tablet was bioequivalent to the 10 mg NOLVADEX tablets.<sup>1</sup>
                  </p>

                  <p id="__p19">A randomized, double-blind trial that evaluated the antiproliferative effects of various doses of tamoxifen in pre-operative breast cancer patients found that low doses of tamoxifen (ie, 1 mg/day or 5 mg/day) produced comparable antiproliferative effects relative to the standard tamoxifen dose (ie, 20 mg/day). In this study, a tamoxifen dose of 1 mg/kg produced concentrations of 4-hydroxytamoxifen in breast tissue that were ~10–20-times greater than the IC50 measured in MCF7 breast cancer cells.<sup>2</sup>
                  </p>

               </div>

               <div id="__sec8" class="sec">

                  <h2 class="head no_bottom_margin" id="__sec8title">SUMMARY</h2>

                  <h4><i>Approved Dosing<sup>1</sup></h4></i>
                  <p id="__p20">For patients with breast cancer, the recommended daily dose is 20-40 mg. Dosages greater than 20 mg per day should be given in divided doses (morning and evening). For treatment of DCIS and for reduction in breast cancer incidence in high risk women the recommended dose is 20 mg daily for 5 years.
                  </p>

                  <h4><i>Dosing Administered in Clinical Trials<sup>1</sup></h4></i>
                  <p id="__p21">In clinical trials of NOLVADEX, patients received doses of 20-40 mg daily
                  <ul>
                    <li>Continuation of therapy beyond five years does not provide additional benefit
                    </li>
                    <li>Reduction in recurrence and mortality was greater in those studies that used tamoxifen for about 5 years than in those that used tamoxifen for a shorter period of therapy
                    </li>
                    <li>There was no indication that doses greater than 20 mg per day were more effective
                    </li>
                  </ul>
                  </p>

                  <h4><i>Duration of Therapy<sup>3-6</sup></h4></i>
                  <p id="__p22"><i>Clinical trial results:</i> In three single agent adjuvant studies in women, one 10 mg NOLVADEX tablet was administered two (ECOG and NATO) or three (Toronto) times a day for two years. In the NSABP B-14 adjuvant study in women with node-negative breast cancer, one 10 mg NOLVADEX tablet was given twice a day for at least 5 years. Results of the B-14 study suggest that continuation of therapy beyond five years does not provide additional benefit. In the EBCTCG 1995 overview, the reduction in recurrence and mortality was greater in those studies that used tamoxifen for about 5 years than in those that used tamoxifen for a shorter period of therapy. There was no indication that doses greater than 20 mg per day were more effective. Current data from clinical trials support 5 years of adjuvant NOLVADEX therapy for patients with breast cancer.
                  </p>

                  <h4><i>Special Considerations<sup>1</sup></h4></i>
                  <h5><i>Special populations</i></h5>
                  <p id="__p23"><i>Clinical trial results:</i> In three single agent adjuvant studies in women, one 10 mg NOLVADEX tablet was administered two (ECOG and NATO) or three (Toronto) times a day for two years. In the NSABP B-14 adjuvant study in women with node-negative breast cancer, one 10 mg NOLVADEX tablet was given twice a day for at least 5 years. Results of the B-14 study suggest that continuation of therapy beyond five years does not provide additional benefit. In the EBCTCG 1995 overview, the reduction in recurrence and mortality was greater in those studies that used tamoxifen for about 5 years than in those that used tamoxifen for a shorter period of therapy. There was no indication that doses greater than 20 mg per day were more effective. Current data from clinical trials support 5 years of adjuvant NOLVADEX therapy for patients with breast cancer.
                  </p>

                  <h5><i>Drug-drug interactions</i></h5>
                  <p id="__p24">In vitro studies showed that erythromycin, cyclosporin, nifedipine and diltiazem competitively inhibited formation of N-desmethyl tamoxifen with apparent K1 of 20, 1, 45 and 30 μM, respectively. The clinical significance of these in vitro studies is unknown.
                  </p>

                  <p id="__p25">Tamoxifen reduced the plasma concentration of letrozole by 37% when these drugs were coadministered. Rifampin, acytochrome P-450 3A4 inducer reduced tamoxifen AUC and Cmax by 86% and 55%, respectively. Aminoglutethimide reduces tamoxifen and N-desmethyl tamoxifen plasma concentrations. Medroxyprogesterone reduces plasma concentrations of N-desmethyl, but not tamoxifen.
                  </p>

               </div>

               <div id="__sec9" class="sec">
                  <h2 class="head no_bottom_margin" id="__sec9title">CONTACT INFORMATION
                  </h2>
                  <p id="__p26">Thank you for your interest in NOLVADEX (tamoxifen citrate) tablets. Please visit us at <a href="http://NOLVADEX.com">http://NOLVADEX.com</a>. If you need additional information or assistance, or if you did not request this information, please contact our medical information specialist Jane Doe at 1-(800)-123-4567 or email us at <a href="mailto:JaneDoe@nolvadexmedinformation.com">JaneDoe@nolvadexmedinformation.com</a>. You may also submit your medical information inquiries using our online submission form at <a href="http://NOLVADEX.com">http://NOLVADEX.com</a>.
                  </p>

               </div>

               <div id="__ref-listid438417" class="sec">
                  <h2 class="head no_bottom_margin" id="__ref-listid438417title">BIBLIOGRAPHY</h2>
                  <div class="ref-list-sec sec" id="reference-list">
                     <ul class="back-ref-list" style="list-style-type:decimal;">

                        <li id="B1"><span>NOLVADEX (tamoxifen citrate) tablets [package insert]:
                              <span class="nowrap ref">[<a class="int-reflink" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/17970s053lbl.pdf">Package Insert</a>]</span>
                        </li>

                        <li id="B2"><span>Decensi A, et al. <span><span class="ref-journal">J Natl Cancer Inst </span>2003;<span class="ref-vol">11</span>:779-90. </span>
                              <span class="nowrap ref"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12783932" target="pmc_ext" onclick="focuswin('pmc_ext')">https://www.ncbi.nlm.nih.gov/pubmed/12783932</a></span>
                        </li>
                        <li id="B3"><span>Bratherton DG, et al.
                              <span><span class="ref-journal">Br J Cancer. </span>1984;<span class="ref-vol">125</span>:199-205. </span>
                              <span class="nowrap ref pubmed"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976875" target="pmc_ext" onclick="focuswin('pmc_ext')">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976875</a></span>
                        </li>
                        <li id="B4"><span>Early Breast Cancer Trialists’ Collaborative Group.
                              <span><span class="ref-journal">Lancet. </span>1998;<span class="ref-vol">351</span>:1451-67. </span>
                              <span class="nowrap ref pubmed"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3430610" target="pmc_ext" onclick="focuswin('pmc_ext')">http://www.ncbi.nlm.nih.gov/pubmed/3430610</a></span>
                        </li>

                        <li id="B5"><span>Fisher B, et al.
                              <span><span class="ref-journal">J Natl Cancer Inst. </span>1992;<span class="ref-vol">11</span>:105-16. </span>
                              <span class="nowrap ref pubmed"><a href=" https://www.ncbi.nlm.nih.gov/pubmed/1627417" target="pmc_ext" onclick="focuswin('pmc_ext')"> https://www.ncbi.nlm.nih.gov/pubmed/1627417</a></span>
                        </li>
                        <li id="B6"><span>Fisher B, et al.
                              <span><span class="ref-journal">New Engl J Med. </span>1989;<span class="ref-vol">320</span>:479-84. </span>
                              <span class="nowrap ref crossref"><a href="https://www.ncbi.nlm.nih.gov/pubmed/2644532" target="pmc_ext" onclick="focuswin('pmc_ext')">https://www.ncbi.nlm.nih.gov/pubmed/2644532</a></span></span>
                        </li>
                     </ul>

                  </div>

               </div>


               <div id="__ffn_sec" class="sec">

                  <div class="fm-sec">

                     <div>

                       <div>
                         <h6 class="courtesy-note no_margin small">
                         Please see full <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdf">Prescribing Information</a>.
                        </h6>
                       </div>

                       <div>
                         <h6 class="courtesy-note no_margin small">
                         Content has been rendered in HTML format using software available from PubReader™. PubReader™ is a trademark of the U. S. National Library of Medicine.
                        </h6>
                       </div>

                     </div>

                      <div>

                         <div>
                            NP-NOL-US-0000 06/19.
                         </div>

                         <div>
                            © 2019 Pharma Company, Inc.
                         </div>

                      </div>

                  </div>

               </div>

            </article>

         </div>
         <div id="jr-scripts"><script src="../lib/js/hand-1.3.8.js"> </script><script src="../lib/js/modernizr.jr.js"> </script><script src="../lib/js/jquery-2.2.3.js"> </script><script src="../lib/js/jquery-migrate-1.4.1.js"> </script><script src="../lib/js/jquery.throttle.js"> </script><script src="../lib/js/jquery.mousewheel.js"> </script><script src="../lib/js/rangeinput.js"> </script><script src="../lib/js/jquery.touchSwipe.js"> </script><script src="../lib/js/jquery.hoverIntent.js"> </script><script src="../lib/js/figpopup.js"> </script><script src="../js/jr.utils.js"> </script><script src="../js/jquery.jr.ft.js"> </script><script src="../js/jquery.jr.pagemanager.js"> </script><script src="../js/jquery.jr.paginationstatus.js"> </script><script src="../js/jquery.jr.pageturnsensor.js"> </script><script src="../js/jquery.jr.pageprogressbar.js"> </script><script src="../js/jquery.jr.links.js"> </script><script src="../js/jquery.jr.historykeeper.js"> </script><script src="../js/jquery.jr.objectbox.js"> </script><script src="../js/jquery.jr.switcher.js"> </script><script src="../js/jquery.jr.panel.js"> </script><script src="../js/jquery.jr.panel.typo.js"> </script><script src="../js/jquery.jr.panel.cmap.js"> </script><script src="../js/jquery.jr.panel.istrip.js"> </script><script src="../js/jquery.jr.fip.js"> </script><script src="../lib/js/jquery.citationexporter.js"></script><script src="../js/jats.reader.js"> </script><script type="text/x-mathjax-config">
              MathJax.Hub.Config({
                SVG: {
                  scale: 90,
                  linebreaks: {
                    automatic: true,
                    width: "container"
                  }
                },
                showProcessingMessages: false,
                messageStyle: "none"
              });
              </script><script type="text/javascript" src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_SVG"></script></div>
      </div>
   </body>
</html>
